…A majority of patients with psychiatric comorbidities secondary to tuberous sclerosis complex (TSC) respond to psychoactive medications, according to a single-centre analysis of clinical records (Chung et al. Ann Clin Psychiatry 2011; 23: 263-269). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…mab – for the treatment of Alzheimer’s disease expect to release phase III data in 2012. Those results may usher in a new era, or may add names to the list of high-profile setbacks in AD therapeutics such as tarenflurbil (Myriad), semagacestat (Lilly/Elan), tramiprosate (Neurochem) and AN1792 (Elan). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with C…
…reports have suggested that calcium channel blockers (e.g. nifedipine, verapamil, diltiazem) may be beneficial in the treatment of neuroleptic-induced tardive dyskinesia (Suddath et al. Pharmacol Biochem Behav 1991; 39: 743-745; Duncan et al. J Clin Psychopharmacol 1990; 10: 414-416). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…tinue…